Literature DB >> 14610209

Development and characterization of novel empty adenovirus capsids and their impact on cellular gene expression.

Jackie L Stilwell1, Douglas M McCarty, Atsuko Negishi, Richard Superfine, R Jude Samulski.   

Abstract

Adenovirus (Ad) has been extensively studied as a eukaryotic viral vector. As these vectors have evolved from first-generation vectors to vectors that contain either very few or no viral genes ("gutless" Ad), significant reductions in the host innate immune response upon infection have been observed. Regardless of these vector improvements an unknown amount of toxicity has been associated with the virion structural proteins. Here we demonstrate the ability to generate high particle numbers (10(11) to 10(12)) of Ad empty virions based on a modification of Cre/lox gutless Ad vectors. Using a battery of analyses (electron microscopy, atomic force microscopy, confocal images, and competition assays) we characterized this reagent and determined that it (i) makes intact virion particles, (ii) competes for receptor binding with wild-type Ad, and (iii) enters the cell proficiently, demonstrating an ability to carry out essential steps of viral entry. To further study the biological impact of these Ad empty virions on infected cells, we carried out DNA microarray analysis. Compared to that for recombinant Ad, the number of mRNAs modulated upon infection was significantly reduced but the expression signatures were similar. This reagent provides a valuable tool for studies of Ad in that researchers can examine the effect of infection in the presence of the virion capsid alone.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14610209      PMCID: PMC262574          DOI: 10.1128/jvi.77.23.12881-12885.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

1.  The role of the nuclear pore complex in adenovirus DNA entry.

Authors:  U F Greber; M Suomalainen; R P Stidwill; K Boucke; M W Ebersold; A Helenius
Journal:  EMBO J       Date:  1997-10-01       Impact factor: 11.598

2.  Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity.

Authors:  G Schiedner; N Morral; R J Parks; Y Wu; S C Koopmans; C Langston; F L Graham; A L Beaudet; S Kochanek
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

3.  A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal.

Authors:  R J Parks; L Chen; M Anton; U Sankar; M A Rudnicki; F L Graham
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

4.  Construction of adenovirus vectors through Cre-lox recombination.

Authors:  S Hardy; M Kitamura; T Harris-Stansil; Y Dai; M L Phipps
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

5.  Generation of an adenovirus vector lacking E1, e2a, E3, and all of E4 except open reading frame 3.

Authors:  M I Gorziglia; C Lapcevich; S Roy; Q Kang; M Kadan; V Wu; P Pechan; M Kaleko
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

6.  Persistence in muscle of an adenoviral vector that lacks all viral genes.

Authors:  H H Chen; L M Mack; R Kelly; M Ontell; S Kochanek; P R Clemens
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

7.  Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy.

Authors:  T Kafri; D Morgan; T Krahl; N Sarvetnick; L Sherman; I Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-15       Impact factor: 11.205

8.  In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted.

Authors:  M Lusky; M Christ; K Rittner; A Dieterle; D Dreyer; B Mourot; H Schultz; F Stoeckel; A Pavirani; M Mehtali
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

9.  In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes.

Authors:  P R Clemens; S Kochanek; Y Sunada; S Chan; H H Chen; K P Campbell; C T Caskey
Journal:  Gene Ther       Date:  1996-11       Impact factor: 5.250

10.  Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing alpha1-antitrypsin after systemic delivery.

Authors:  W K O'Neal; H Zhou; N Morral; E Aguilar-Cordova; J Pestaner; C Langston; B Mull; Y Wang; A L Beaudet; B Lee
Journal:  Hum Gene Ther       Date:  1998-07-20       Impact factor: 5.695

View more
  19 in total

Review 1.  Current strategies and future directions for eluding adenoviral vector immunity.

Authors:  Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Gene Ther       Date:  2006-04       Impact factor: 4.391

Review 2.  Transductional targeting of adenovirus vectors for gene therapy.

Authors:  J N Glasgow; M Everts; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-27       Impact factor: 5.987

Review 3.  Helper-dependent adenoviral vectors in experimental gene therapy.

Authors:  Alicja Józkowicz; Józef Dulak
Journal:  Acta Biochim Pol       Date:  2005-08-04       Impact factor: 2.149

Review 4.  Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances.

Authors:  Guy L Odom; Paul Gregorevic; Jeffrey S Chamberlain
Journal:  Biochim Biophys Acta       Date:  2006-09-26

Review 5.  Adenoviral vector immunity: its implications and circumvention strategies.

Authors:  Yadvinder S Ahi; Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Gene Ther       Date:  2011-08       Impact factor: 4.391

6.  Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomas.

Authors:  Mirjana Urosevic; Kazuyasu Fujii; Bastien Calmels; Elisabeth Laine; Nikita Kobert; Bruce Acres; Reinhard Dummer
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

7.  Adenovirus induction of IRF3 occurs through a binary trigger targeting Jun N-terminal kinase and TBK1 kinase cascades and type I interferon autocrine signaling.

Authors:  Marcelo Nociari; Oksana Ocheretina; Mary Murphy; Erik Falck-Pedersen
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

8.  Viral capsid is a pathogen-associated molecular pattern in adenovirus keratitis.

Authors:  Ashish V Chintakuntlawar; Xiaohong Zhou; Jaya Rajaiya; James Chodosh
Journal:  PLoS Pathog       Date:  2010-04-15       Impact factor: 6.823

9.  Sustained viral gene delivery through core-shell fibers.

Authors:  I-Chien Liao; Sulin Chen; Jason B Liu; Kam W Leong
Journal:  J Control Release       Date:  2009-06-17       Impact factor: 9.776

Review 10.  Innate immunity to adenovirus.

Authors:  Rodinde Hendrickx; Nicole Stichling; Jorien Koelen; Lukasz Kuryk; Agnieszka Lipiec; Urs F Greber
Journal:  Hum Gene Ther       Date:  2014-04-08       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.